Novavax's prototype vaccine effective against omicron variants, study finds

In a late-stage trial, Novavax's prototype COVID-19 vaccine increased neutralizing antibody titers up to 34 times higher than primary vaccination among adults, with a "significant boost" against omicron variants and subvariants BA.1, BA.2 and BA.5. 

In the same study, one booster shot increased neutralizing titers 2.7-fold among teenagers between 12 and 17 years old, Novavax said Oct. 12. 

The vaccine-maker, which began distributing its COVID-19 vaccine after gaining the FDA and CDC's authorization in July, said the prototype booster doses were well tolerated and side effects were mainly mild to moderate.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy
.
 

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Articles We Think You'll Like